Tag: gene therapy for inherited genetic disorders market size

Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.

Gene Therapy For Inherited Genetic Disorders Market Forecast: Value Set To Climb From $4.83 Billion To $9.68 Billion

The market for gene therapy targeting inherited genetic disorders has experienced substantial growth recently. This market is projected to expand from $4.05 billion in 2025 to $4.84 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 19.3%. The market’s historical expansion was driven by factors including the limited availability of advanced gene therapy techniques, a reliance on conventional treatments for genetic conditions, a growing incidence of inherited genetic diseases, early clinical investigations into viral vectors, and increasing awareness regarding rare disease management.

The gene therapy for inherited genetic disorders market size is projected to experience substantial expansion in the coming years. This sector is anticipated to reach a valuation of $9.69 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 19.0%. Key factors driving this growth during the forecast period include advancements in novel viral vectors and gene editing technologies, the broadening scope of RNA-based therapies, increased adoption of ex vivo stem cell treatments, growing investments in personalized gene therapies, and enhanced capabilities in hospitals and specialty clinics for administering gene therapy. Prominent trends expected over the forecast period encompass the wider application of viral vector-based therapies for rare genetic conditions, an increase in ex vivo gene therapy uses, greater uptake of RNA-based therapeutics, a heightened focus on addressing neurological and ophthalmic disorders, and the incorporation of personalized medicine into gene therapy practices.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=27293&type=smp&name=Gene%20Therapy%20For%20Inherited%20Genetic%20Disorders%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Gene Therapy For Inherited Genetic Disorders Market Demand Drivers: What’s Powering Industry Growth?

The increasing need for personalized medicine is anticipated to drive the expansion of the gene therapy for inherited genetic disorders market moving ahead. This approach involves customizing medical interventions based on an individual’s genetic makeup and unique attributes to achieve optimal patient care. The prevalence of personalized medicine is growing, driven by progress in genetic technologies that facilitate more accessible and cost-effective treatment customization according to an individual’s distinct genetic profile. By adapting treatments to suit each patient’s specific genetic profile, personalized medicine enhances gene therapy, guaranteeing accurate gene targeting and delivery, thereby boosting efficacy and minimizing adverse reactions. As an example, in February 2024, data from the Personalized Medicine Coalition, a US-based non-profit organization, indicated that in 2023, the United States Food and Drug Administration (FDA) granted approval to 16 new personalized treatments intended for rare disease patients, which is an increase from 6 in 2022. Among the personalized treatments newly approved for 2023 were also seven cancer drugs and three for other diseases and conditions. Consequently, the escalating demand for personalized medicine is propelling the growth of the gene therapy for inherited genetic disorders market.

Gene Therapy For Inherited Genetic Disorders Market Segment Analysis: What Are The Core Market Categories?

The gene therapy for inherited genetic disorders market covered in this report is segmented –

1) By Type: Viral Vector-Based Therapies, Gene Editing Techniques, Ribonucleic Acid-Based Therapies, Ex Vivo Gene Therapy

2) By Application: Inherited Metabolic Disorders, Neurological Disorders, Cardiovascular Disorders, Musculoskeletal Disorders, Ophthalmic Disorders

3) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users

Subsegments:

1) By Viral Vector-Based Therapies: Adenovirus Vectors, Adeno-Associated Virus (AAV) Vectors, Lentivirus Vectors

2) By Gene Editing Techniques: Zinc Finger Nucleases (ZFNs), Transcription Activator-Like Effector Nucleases (TALENs), Meganucleases

3) By Ribonucleic Acid-Based Therapies: Small Interfering Ribonucleic Acid, Antisense Oligonucleotides (ASOs), Messenger Ribonucleic Acid (mRNA) Therapies

4) By Ex Vivo Gene Therapy: Hematopoietic Stem Cell Gene Therapy, Mesenchymal Stem Cell Gene Therapy, Induced Pluripotent Stem Cell (iPSC) Therapy

Gene Therapy For Inherited Genetic Disorders Market Innovation Trends: What Developments Are Reshaping The Industry?

Companies operating within the gene therapy for inherited genetic disorders market are prioritizing the development of innovative solutions, such as ex-vivo CRISPR/Cas9-based gene-edited cell therapies. This effort aims to address the increasing demand for single-administration, potentially curative treatments that can mitigate lifelong reliance on transfusions, frequent hospitalizations, and substantial chronic-care expenditures associated with inherited blood and metabolic disorders. The ex-vivo CRISPR/Cas9 gene-edited cell therapy process entails harvesting a patient’s hematopoietic stem cells, employing CRISPR/Cas9 to precisely modify disease-causing genes (or regulatory elements that elevate protective fetal hemoglobin), and subsequently reintroducing the modified cells so they can engraft and deliver prolonged therapeutic benefits. For instance, in December 2023, Vertex Pharmaceuticals, a US-based biopharmaceutical company, obtained U.S. Food and Drug Administration (FDA) approval and commercial availability for CASGEVY (exagamglogene autotemcel). This is a CRISPR/Cas9-based, ex-vivo gene-edited cell therapy developed for sickle cell disease, an inherited genetic disorder. CASGEVY is manufactured from a patient’s own hematopoietic stem cells that undergo gene editing to increase fetal hemoglobin. The product’s makeup is centered on autologous stem cells modified with CRISPR/Cas9; its function is to raise durable fetal hemoglobin levels, which prevent red-blood-cell sickling. Distinctive features include precise genome editing (CRISPR/Cas9) performed ex vivo and a one-time administration with a lasting effect. Its primary application is the treatment of severe sickle cell disease, with related indications currently under regulatory review. The main benefits observed in trials include significant reductions in vaso-occlusive crises and transfusion dependence compared with previous standard-of-care.

Gene Therapy For Inherited Genetic Disorders Market Top Companies Driving Competitive Growth

Major companies operating in the gene therapy for inherited genetic disorders market are Sanofi S.A., Novartis AG, Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Genentech, Biomarin Pharmaceutical Inc, Sarepta Therapeutics Inc., Krystal Biotech Inc., Rocket Pharmaceuticals Inc., Sangamo Therapeutics Inc., REGENXBIO Inc., Passage Bio Inc., Voyager Therapeutics Inc., Generation Bio Co., Avrobio Inc, Editas Medicine Inc., MeiraGTx Holdings Plc, uniQure N.V., Intellia Therapeutics Inc., Bluebird Bio Inc, 4D Molecular Therapeutics Inc., CRISPR Therapeutics AG

View The Full Gene Therapy For Inherited Genetic Disorders Market Report:

https://thebusinessresearchcompany.com/report/gene-therapy-for-inherited-genetic-disorders-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Gene Therapy For Inherited Genetic Disorders Market Regional Distribution: Which Areas Power Market Growth?

North America was the largest region in the gene therapy for inherited genetic disorders market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene therapy for inherited genetic disorders market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Gene Therapy For Inherited Genetic Disorders Market Size Forecast: How Large Could The Market Become By 2030?

The market for gene therapy targeting inherited genetic disorders has experienced swift expansion over recent years. Projected to rise from $4.05 billion in 2025 to $4.84 billion in 2026, this represents a compound annual growth rate (CAGR) of 19.3%. Historically, this growth was driven by factors such as the restricted access to sophisticated gene therapy methods, dependence on traditional approaches for treating genetic conditions, a growing incidence of inherited genetic diseases, foundational clinical investigations involving viral vectors, and heightened awareness surrounding the management of rare diseases.

The gene therapy market for inherited genetic disorders is projected to experience significant expansion in the coming years, reaching a value of $9.69 billion by 2030, with a compound annual growth rate (CAGR) of 19.0%. This forecasted growth is driven by advancements in novel viral vectors and gene editing tools, the broadening scope of RNA-based treatments, increased use of ex vivo stem cell therapies, heightened investment in customized gene therapies, and enhanced capabilities in hospitals and specialty clinics for administering these therapies. Key trends shaping the forecast period include the proliferation of viral vector-based approaches for rare genetic conditions, greater adoption of ex vivo gene therapy techniques, rising utilization of RNA-focused therapeutics, a growing emphasis on addressing neurological and ophthalmic disorders, and the integration of personalized medicine into gene therapy strategies.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27293&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Gene Therapy For Inherited Genetic Disorders Market Expansion Drivers: What Is Shaping Future Growth?

The growing demand for tailored medical approaches is anticipated to accelerate the expansion of the gene therapy market focused on inherited genetic disorders. Personalized medicine involves adapting treatments to a patient’s genetic profile and individual characteristics in order to deliver optimized care. This trend is gaining momentum due to progress in genetic technologies, which have made it simpler and more cost-effective to customize therapies according to a person’s unique genetic composition. Such customization boosts gene therapy by aligning treatments with each patient’s distinct genetic blueprint, enabling precise gene targeting and delivery while improving efficacy and minimizing adverse effects. For example, in February 2024, the Personalized Medicine Coalition—a nonprofit organization based in the United States—reported that the U.S. Food and Drug Administration (FDA) approved 16 new personalized therapies for rare disease patients in 2023, compared with 6 in 2022. Among these newly approved personalized treatments for 2023 were seven cancer drugs and three medications targeting other conditions. Consequently, the rising demand for personalized medicine is fueling growth in the gene therapy market for inherited genetic disorders.

Gene Therapy For Inherited Genetic Disorders Market Segments: Where Are The Largest Growth Opportunities?

The gene therapy for inherited genetic disorders market covered in this report is segmented –

1) By Type: Viral Vector-Based Therapies, Gene Editing Techniques, Ribonucleic Acid-Based Therapies, Ex Vivo Gene Therapy

2) By Application: Inherited Metabolic Disorders, Neurological Disorders, Cardiovascular Disorders, Musculoskeletal Disorders, Ophthalmic Disorders

3) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users

Subsegments:

1) By Viral Vector-Based Therapies: Adenovirus Vectors, Adeno-Associated Virus (AAV) Vectors, Lentivirus Vectors

2) By Gene Editing Techniques: Zinc Finger Nucleases (ZFNs), Transcription Activator-Like Effector Nucleases (TALENs), Meganucleases

3) By Ribonucleic Acid-Based Therapies: Small Interfering Ribonucleic Acid, Antisense Oligonucleotides (ASOs), Messenger Ribonucleic Acid (mRNA) Therapies

4) By Ex Vivo Gene Therapy: Hematopoietic Stem Cell Gene Therapy, Mesenchymal Stem Cell Gene Therapy, Induced Pluripotent Stem Cell (iPSC) Therapy

Gene Therapy For Inherited Genetic Disorders Market Strategic Trends: What Is Defining The Next Phase Of Growth?

Key players in the gene therapy market for inherited genetic disorders are concentrating on developing advanced treatments, particularly ex-vivo CRISPR/Cas9-based gene-edited cell therapies, to address the growing need for one-time, potentially curative options that minimize reliance on lifelong blood transfusions, frequent hospital stays, and expensive chronic care for inherited blood and metabolic conditions. In this approach, a patient’s hematopoietic stem cells are collected and precisely modified using CRISPR/Cas9 technology to correct disease-causing genes or enhance regulatory elements that boost protective fetal hemoglobin; these edited cells are then reinfused, allowing them to engraft and deliver sustained therapeutic outcomes. A notable example occurred in December 2023 when Vertex Pharmaceuticals, a U.S.-based biopharmaceutical firm, secured approval from the U.S. Food and Drug Administration (FDA) and launched CASGEVY (exagamglogene autotemcel), a CRISPR/Cas9-based ex-vivo gene-edited cell therapy designed for sickle cell disease, an inherited genetic disorder. This therapy is derived from the patient’s own hematopoietic stem cells, which undergo gene editing to elevate fetal hemoglobin levels; its composition features autologous stem cells modified with CRISPR/Cas9, and its mechanism works by generating durable fetal hemoglobin concentrations that inhibit red blood cell sickling. Distinct characteristics include ex-vivo precise genome editing via CRISPR/Cas9 and a single administration that offers lasting effects; CASGEVY’s primary use is for severe sickle cell disease and similar indications under regulatory review, while clinical trials have demonstrated significant reductions in vaso-occlusive crises and transfusion needs compared to conventional treatments.

Gene Therapy For Inherited Genetic Disorders Market Major Participants And Competitive Dynamics

Major companies operating in the gene therapy for inherited genetic disorders market are Sanofi S.A., Novartis AG, Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Genentech, Biomarin Pharmaceutical Inc, Sarepta Therapeutics Inc., Krystal Biotech Inc., Rocket Pharmaceuticals Inc., Sangamo Therapeutics Inc., REGENXBIO Inc., Passage Bio Inc., Voyager Therapeutics Inc., Generation Bio Co., Avrobio Inc, Editas Medicine Inc., MeiraGTx Holdings Plc, uniQure N.V., Intellia Therapeutics Inc., Bluebird Bio Inc, 4D Molecular Therapeutics Inc., CRISPR Therapeutics AG

Access The Complete Gene Therapy For Inherited Genetic Disorders Market Report:

https://www.thebusinessresearchcompany.com/report/gene-therapy-for-inherited-genetic-disorders-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Gene Therapy For Inherited Genetic Disorders Market Geographic Landscape: Which Region Dominates Industry Growth?

North America was the largest region in the gene therapy for inherited genetic disorders market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene therapy for inherited genetic disorders market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Is The Market Value Of The Gene Therapy For Inherited Genetic Disorders Market Projected To Expand During 2026–2030?

The market size for gene therapy addressing inherited genetic disorders has seen swift expansion recently. It will grow from $4.05 billion in 2025 to $4.84 billion in 2026 at a compound annual growth rate (CAGR) of 19.3%. This historical growth can be attributed to several factors including the limited availability of advanced gene therapy techniques, a reliance on conventional treatments for genetic disorders, the increasing prevalence of inherited genetic diseases, early clinical research focused on viral vectors, and a rising awareness of rare disease management.

The gene therapy for inherited genetic disorders market is anticipated to experience significant expansion in the coming years. It is projected to reach **$9.69 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 19.0%.** This growth during the forecast period is fueled by the development of innovative viral vectors and gene editing technologies, the broadening scope of RNA-based therapies, increased implementation of ex vivo stem cell therapies, growing investment in personalized gene therapies, and the enhanced capacity of hospitals and specialty clinics for gene therapy administration. Prominent trends expected in the forecast period include the extended use of viral vector-based therapies for rare genetic disorders, an increase in ex vivo gene therapy applications, wider adoption of RNA-based therapeutics, an intensifying focus on addressing neurological and ophthalmic disorders, and the incorporation of personalized medicine into gene therapy.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27293&type=smp

What Key Growth Drivers Are Influencing The Gene Therapy For Inherited Genetic Disorders Market?

The increasing need for personalized medicine is projected to fuel the expansion of the gene therapy for inherited genetic disorders market in the future. Personalized medicine involves customizing medical interventions based on an individual’s unique genetic profile and personal characteristics to achieve optimal care. This approach is gaining traction due to advancements in genetic technologies, making it simpler and more affordable to tailor treatments to an individual’s specific genetic makeup. Personalized medicine enhances gene therapy by adapting treatments to each patient’s distinct genetic profile, thereby ensuring precise gene targeting and delivery, improving effectiveness, and minimizing adverse effects. For example, in February 2024, the US-based non-profit organization, Personalized Medicine Coalition, reported that in 2023, the United States Food and Drug Administration (FDA) sanctioned 16 new personalized treatments for rare disease patients, a significant rise from 6 in 2022. The personalized treatments newly approved in 2023 also encompassed seven cancer drugs and three for other diseases and conditions. As a result, the growing demand for personalized medicine is a primary driver for the growth of the gene therapy for inherited genetic disorders market.

What Segment Categories Are Evaluated In The Gene Therapy For Inherited Genetic Disorders Market Study?

The gene therapy for inherited genetic disorders market covered in this report is segmented –

1) By Type: Viral Vector-Based Therapies, Gene Editing Techniques, Ribonucleic Acid-Based Therapies, Ex Vivo Gene Therapy

2) By Application: Inherited Metabolic Disorders, Neurological Disorders, Cardiovascular Disorders, Musculoskeletal Disorders, Ophthalmic Disorders

3) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users

Subsegments:

1) By Viral Vector-Based Therapies: Adenovirus Vectors, Adeno-Associated Virus (AAV) Vectors, Lentivirus Vectors

2) By Gene Editing Techniques: Zinc Finger Nucleases (ZFNs), Transcription Activator-Like Effector Nucleases (TALENs), Meganucleases

3) By Ribonucleic Acid-Based Therapies: Small Interfering Ribonucleic Acid, Antisense Oligonucleotides (ASOs), Messenger Ribonucleic Acid (mRNA) Therapies

4) By Ex Vivo Gene Therapy: Hematopoietic Stem Cell Gene Therapy, Mesenchymal Stem Cell Gene Therapy, Induced Pluripotent Stem Cell (iPSC) Therapy

What Trends Are Affecting The Gene Therapy For Inherited Genetic Disorders Market Dynamics?

Leading companies within the gene therapy for inherited genetic disorders market are concentrating on the development of advanced solutions, such as ex-vivo CRISPR/Cas9-based gene-edited cell therapies, to address the escalating need for one-time, potentially curative treatments. These innovations aim to lessen lifelong reliance on transfusions, frequent hospitalizations, and the high expenditures associated with chronic care for inherited blood and metabolic disorders. Ex-vivo CRISPR/Cas9 gene-edited cell therapy entails collecting a patient’s hematopoietic stem cells, utilizing CRISPR/Cas9 to precisely edit disease-causing genes (or regulatory elements that increase protective fetal hemoglobin), and subsequently reinfusing the modified cells so they can engraft and deliver lasting therapeutic benefits. For example, in December 2023, Vertex Pharmaceuticals, a US-based biopharmaceutical company, obtained U.S. Food and Drug Administration (FDA) approval and achieved commercial availability for CASGEVY (exagamglogene autotemcel). This is an ex-vivo, CRISPR/Cas9-based gene-edited cell therapy specifically for sickle cell disease, an inherited genetic disorder. CASGEVY is derived from a patient’s own hematopoietic stem cells, which are gene-edited to elevate fetal hemoglobin. The product’s makeup features autologous stem cells modified with CRISPR/Cas9; its function is to raise durable fetal hemoglobin levels, thereby preventing red-blood-cell sickling. Unique attributes include precise genome editing (CRISPR/Cas9) performed ex vivo and a one-time administration delivering a durable effect. Its primary application is the treatment of severe sickle cell disease (and related indications currently under regulatory evaluation), with trials demonstrating significant reductions in vaso-occlusive crises and transfusion dependence compared to previous standard-of-care.

Which Companies Are Influencing The Gene Therapy For Inherited Genetic Disorders Market?

Major companies operating in the gene therapy for inherited genetic disorders market are Sanofi S.A., Novartis AG, Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Genentech, Biomarin Pharmaceutical Inc, Sarepta Therapeutics Inc., Krystal Biotech Inc., Rocket Pharmaceuticals Inc., Sangamo Therapeutics Inc., REGENXBIO Inc., Passage Bio Inc., Voyager Therapeutics Inc., Generation Bio Co., Avrobio Inc, Editas Medicine Inc., MeiraGTx Holdings Plc, uniQure N.V., Intellia Therapeutics Inc., Bluebird Bio Inc, 4D Molecular Therapeutics Inc., CRISPR Therapeutics AG

Access The Complete Gene Therapy For Inherited Genetic Disorders Market Report:

https://www.thebusinessresearchcompany.com/report/gene-therapy-for-inherited-genetic-disorders-global-market-report

Which Region Holds The Largest Share In The Gene Therapy For Inherited Genetic Disorders Market?

North America was the largest region in the gene therapy for inherited genetic disorders market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene therapy for inherited genetic disorders market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Gene Therapy For Inherited Genetic Disorders Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=27293&type=smp

Browse Through More Reports Similar to the Global Gene Therapy For Inherited Genetic Disorders Market 2026, By The Business Research Company

Asphalt Mixing Plants Market Report 2026

https://www.thebusinessresearchcompany.com/report/asphalt-mixing-plants-global-market-report

Asphalt Pavers Market Report 2026

https://www.thebusinessresearchcompany.com/report/asphalt-pavers-global-market-report

Asphalt Additives Market Report 2026

https://www.thebusinessresearchcompany.com/report/asphalt-additives-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Projected Increase In Market Value Of The Gene Therapy For Inherited Genetic Disorders Market During 2026–2030?

The gene therapy for inherited genetic disorders market has witnessed rapid growth in recent years. It is expected to expand from $4.05 billion in 2025 to $4.84 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 19.3%. Historically, this growth can be attributed to several factors including the restricted availability of advanced gene therapy techniques, the reliance on conventional treatments for genetic disorders, a rise in the prevalence of inherited genetic diseases, early clinical research focusing on viral vectors, and increasing awareness regarding rare disease management.

The gene therapy for inherited genetic disorders market size is anticipated to experience substantial growth in the coming years, with projections indicating it will reach $9.69 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 19.0%. This expansion during the forecast period is propelled by the ongoing development of innovative viral vectors and gene editing technologies, the broadening application of RNA-based therapies, an increasing adoption rate of ex vivo stem cell therapies, rising investments in personalized gene therapies, and the enhanced capabilities of hospitals and specialty clinics for gene therapy administration. Significant trends expected in this period include the wider application of viral vector-based therapies for rare genetic disorders, an increase in ex vivo gene therapy applications, the growing acceptance of RNA-based therapeutics, a heightened focus on treating neurological and ophthalmic disorders, and the integration of personalized medicine principles within gene therapy.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27293&type=smp

Which Major Drivers Are Influencing The Expansion Of The Gene Therapy For Inherited Genetic Disorders Market?

The expanding need for personalized medicine is anticipated to drive the advancement of the gene therapy for inherited genetic disorders market in the future. This approach involves customizing medical treatments based on an individual’s genetic blueprint and unique characteristics to provide optimal care. Its prevalence is on the rise, spurred by developments in genetic technologies that facilitate easier and more cost-effective customization of therapies according to a person’s distinct genetic composition. Personalized medicine significantly enhances gene therapy by adapting treatments to each patient’s specific genetic profile, thereby guaranteeing accurate gene targeting and delivery, boosting efficacy, and minimizing adverse reactions. As an illustration, in February 2024, data from the US-based non-profit Personalized Medicine Coalition indicated that the United States Food and Drug Administration (FDA) sanctioned 16 novel personalized treatments for patients with rare diseases in 2023, an increase from 6 approvals in 2022. Among the personalized treatments newly approved in 2023 were also seven medications for cancer and three for various other illnesses and conditions. Consequently, the increasing requirement for personalized medicine is fueling the expansion of the gene therapy for inherited genetic disorders market.

Which Segments Define The Gene Therapy For Inherited Genetic Disorders Market Segment Structure?

The gene therapy for inherited genetic disorders market covered in this report is segmented –

1) By Type: Viral Vector-Based Therapies, Gene Editing Techniques, Ribonucleic Acid-Based Therapies, Ex Vivo Gene Therapy

2) By Application: Inherited Metabolic Disorders, Neurological Disorders, Cardiovascular Disorders, Musculoskeletal Disorders, Ophthalmic Disorders

3) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users

Subsegments:

1) By Viral Vector-Based Therapies: Adenovirus Vectors, Adeno-Associated Virus (AAV) Vectors, Lentivirus Vectors

2) By Gene Editing Techniques: Zinc Finger Nucleases (ZFNs), Transcription Activator-Like Effector Nucleases (TALENs), Meganucleases

3) By Ribonucleic Acid-Based Therapies: Small Interfering Ribonucleic Acid, Antisense Oligonucleotides (ASOs), Messenger Ribonucleic Acid (mRNA) Therapies

4) By Ex Vivo Gene Therapy: Hematopoietic Stem Cell Gene Therapy, Mesenchymal Stem Cell Gene Therapy, Induced Pluripotent Stem Cell (iPSC) Therapy

Which Trends Are Contributing To Changes In The Gene Therapy For Inherited Genetic Disorders Market?

Leading firms within the gene therapy for inherited genetic disorders market are concentrating on creating novel approaches, including ex-vivo CRISPR/Cas9-based gene-edited cell therapies. This focus aims to address the growing need for single-application, potentially curative remedies that diminish ongoing reliance on transfusions, frequent hospital stays, and substantial long-term care expenses associated with inherited blood and metabolic conditions. This ex-vivo CRISPR/Cas9 gene-edited cell therapy method entails collecting a patient’s hematopoietic stem cells, employing CRISPR/Cas9 to accurately modify genes responsible for disease (or elements that boost protective fetal hemoglobin), and subsequently reintroducing these altered cells to enable engraftment and deliver sustained therapeutic advantages. As an illustration, in December 2023, the US-based biopharmaceutical company Vertex Pharmaceuticals secured U.S. Food and Drug Administration (FDA) approval and initiated commercial release for CASGEVY (exagamglogene autotemcel). This treatment is a CRISPR/Cas9-based, ex-vivo gene-edited cell therapy designed for sickle cell disease, an inherited genetic disorder. CASGEVY is created using a patient’s own hematopoietic stem cells, which are genetically altered to elevate fetal hemoglobin. The therapy’s makeup primarily consists of autologous stem cells modified via CRISPR/Cas9. Its purpose is to achieve sustained increases in fetal hemoglobin levels, thereby preventing the sickling of red blood cells. Noteworthy attributes include accurate genome editing (CRISPR/Cas9) conducted outside the body and a single dose providing lasting results. Its chief use is for severe sickle cell disease (with other related conditions currently undergoing regulatory assessment), and trial outcomes have demonstrated significant decreases in vaso-occlusive crises and the need for transfusions when compared to previous standard treatments.

Who Are The Established Players Within The Gene Therapy For Inherited Genetic Disorders Market?

Major companies operating in the gene therapy for inherited genetic disorders market are Sanofi S.A., Novartis AG, Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Genentech, Biomarin Pharmaceutical Inc, Sarepta Therapeutics Inc., Krystal Biotech Inc., Rocket Pharmaceuticals Inc., Sangamo Therapeutics Inc., REGENXBIO Inc., Passage Bio Inc., Voyager Therapeutics Inc., Generation Bio Co., Avrobio Inc, Editas Medicine Inc., MeiraGTx Holdings Plc, uniQure N.V., Intellia Therapeutics Inc., Bluebird Bio Inc, 4D Molecular Therapeutics Inc., CRISPR Therapeutics AG

Get The Full Gene Therapy For Inherited Genetic Disorders Market Report:

https://www.thebusinessresearchcompany.com/report/gene-therapy-for-inherited-genetic-disorders-global-market-report

Where Is The Gene Therapy For Inherited Genetic Disorders Market Most Concentrated Geographically?

North America was the largest region in the gene therapy for inherited genetic disorders market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene therapy for inherited genetic disorders market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Gene Therapy For Inherited Genetic Disorders Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/gene-therapy-for-inherited-genetic-disorders-global-market-report

Browse Through More Reports Similar to the Global Gene Therapy For Inherited Genetic Disorders Market 2026, By The Business Research Company

Asphalt Mixing Plants Market Report 2026

https://www.thebusinessresearchcompany.com/report/asphalt-mixing-plants-global-market-report

Asphalt Pavers Market Report 2026

https://www.thebusinessresearchcompany.com/report/asphalt-pavers-global-market-report

Asphalt Additives Market Report 2026

https://www.thebusinessresearchcompany.com/report/asphalt-additives-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Valuation Is Forecasted For The Gene Therapy For Inherited Genetic Disorders Market By 2030 Starting From Its 2026 Size?

The gene therapy for inherited genetic disorders market size has seen significant expansion in recent years. This market is projected to expand from $4.05 billion in 2025 to $4.84 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 19.3%. The growth observed in the historic period stems from several factors, including the limited availability of advanced gene therapy techniques, reliance on conventional treatments for genetic disorders, an increasing prevalence of inherited genetic diseases, early clinical research on viral vectors, and rising awareness of rare disease management.

The gene therapy for inherited genetic disorders market size is projected to experience substantial expansion over the coming years, reaching $9.69 billion by 2030, driven by a compound annual growth rate (CAGR) of 19.0%. This anticipated growth stems from several factors, including the advancement of novel viral vectors and gene editing technologies, the broader application of RNA-based therapies, the increased uptake of ex vivo stem cell treatments, growing investments in personalized gene therapies, and the enhanced capacity of hospitals and specialty clinics for administering gene therapy. Key trends anticipated during this period encompass the wider deployment of viral vector-based therapies for rare genetic conditions, an increase in ex vivo gene therapy applications, the growing acceptance of RNA-based therapeutics, a heightened emphasis on addressing neurological and ophthalmic disorders, and the incorporation of personalized medicine into gene therapy practices.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27293&type=smp

Which Market Drivers Are Supporting The Expansion Of The Gene Therapy For Inherited Genetic Disorders Market?

The increasing need for personalized medicine is anticipated to drive expansion in the gene therapy for inherited genetic disorders market moving ahead. Personalized medicine involves customizing medical interventions based on a patient’s unique genetic makeup and individual traits to achieve optimal healthcare outcomes. The adoption of personalized medicine is growing, fueled by progress in genetic technologies that facilitate easier and more cost-effective customization of treatments for each person’s distinct genetic composition. This approach enhances gene therapy by adapting treatments to an individual’s specific genetic profile, thereby guaranteeing accurate gene targeting and delivery, boosting efficacy, and minimizing adverse reactions. As an illustration, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that in 2023, the United States Food and Drug Administration (FDA) cleared 16 novel personalized treatments for patients with rare diseases, a significant rise from 6 in 2022. Among the personalized treatments newly sanctioned in 2023 were also seven medications for cancer and three for various other illnesses and conditions. Consequently, the escalating demand for personalized medicine is propelling the expansion of the gene therapy for inherited genetic disorders market.

Which Segment Categories Define The Gene Therapy For Inherited Genetic Disorders Market?

The gene therapy for inherited genetic disorders market covered in this report is segmented –

1) By Type: Viral Vector-Based Therapies, Gene Editing Techniques, Ribonucleic Acid-Based Therapies, Ex Vivo Gene Therapy

2) By Application: Inherited Metabolic Disorders, Neurological Disorders, Cardiovascular Disorders, Musculoskeletal Disorders, Ophthalmic Disorders

3) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users

Subsegments:

1) By Viral Vector-Based Therapies: Adenovirus Vectors, Adeno-Associated Virus (AAV) Vectors, Lentivirus Vectors

2) By Gene Editing Techniques: Zinc Finger Nucleases (ZFNs), Transcription Activator-Like Effector Nucleases (TALENs), Meganucleases

3) By Ribonucleic Acid-Based Therapies: Small Interfering Ribonucleic Acid, Antisense Oligonucleotides (ASOs), Messenger Ribonucleic Acid (mRNA) Therapies

4) By Ex Vivo Gene Therapy: Hematopoietic Stem Cell Gene Therapy, Mesenchymal Stem Cell Gene Therapy, Induced Pluripotent Stem Cell (iPSC) Therapy

What Major Market Trends Are Driving Changes In The Gene Therapy For Inherited Genetic Disorders Market?

Companies active in the gene therapy for inherited genetic disorders market are concentrating on developing inventive solutions, such as ex-vivo CRISPR/Cas9-based gene-edited cell therapies, to address the increasing demand for single-application, potentially curative treatments. These therapies aim to lessen lifelong reliance on transfusions, frequent hospitalizations, and substantial chronic-care expenses linked to inherited blood and metabolic disorders. Ex-vivo CRISPR/Cas9 gene-edited cell therapy involves extracting a patient’s hematopoietic stem cells, precisely editing disease-causing genes (or regulatory elements that boost protective fetal hemoglobin) using CRISPR/Cas9, and then reinfusing these modified cells so they engraft and deliver enduring therapeutic benefits. For example, in December 2023, Vertex Pharmaceuticals, a US-based biopharmaceutical company, obtained U.S. Food and Drug Administration (FDA) approval and achieved commercial availability for CASGEVY (exagamglogene autotemcel). This is a CRISPR/Cas9-based, ex-vivo gene-edited cell therapy designed for sickle cell disease, an inherited genetic disorder. CASGEVY is created from a patient’s own hematopoietic stem cells that are gene edited to increase fetal hemoglobin. The product’s makeup centers on autologous stem cells modified with CRISPR/Cas9; its function is to elevate lasting fetal hemoglobin levels to prevent red-blood-cell sickling; unique attributes include precise genome editing (CRISPR/Cas9) performed ex vivo and a one-time administration with durable effect; its main application is treating severe sickle cell disease (with related indications currently under regulatory review), and the principal benefits observed in trials are considerable reductions in vaso-occlusive crises and transfusion dependence when compared to the prior standard-of-care.

Who Are The Top Companies Competing In The Gene Therapy For Inherited Genetic Disorders Market?

Major companies operating in the gene therapy for inherited genetic disorders market are Sanofi S.A., Novartis AG, Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Genentech, Biomarin Pharmaceutical Inc, Sarepta Therapeutics Inc., Krystal Biotech Inc., Rocket Pharmaceuticals Inc., Sangamo Therapeutics Inc., REGENXBIO Inc., Passage Bio Inc., Voyager Therapeutics Inc., Generation Bio Co., Avrobio Inc, Editas Medicine Inc., MeiraGTx Holdings Plc, uniQure N.V., Intellia Therapeutics Inc., Bluebird Bio Inc, 4D Molecular Therapeutics Inc., CRISPR Therapeutics AG

Read the full gene therapy for inherited genetic disorders market report here:

https://www.thebusinessresearchcompany.com/report/gene-therapy-for-inherited-genetic-disorders-global-market-report

How Is The Gene Therapy For Inherited Genetic Disorders Market Distributed Across Key Geographic Regions?

North America was the largest region in the gene therapy for inherited genetic disorders market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene therapy for inherited genetic disorders market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Gene Therapy For Inherited Genetic Disorders Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=27293&type=smp

Browse Through More Reports Similar to the Global Gene Therapy For Inherited Genetic Disorders Market 2026, By The Business Research Company

Asphalt Mixing Plants Market Report 2026

https://www.thebusinessresearchcompany.com/report/asphalt-mixing-plants-global-market-report

Asphalt Pavers Market Report 2026

https://www.thebusinessresearchcompany.com/report/asphalt-pavers-global-market-report

Asphalt Additives Market Report 2026

https://www.thebusinessresearchcompany.com/report/asphalt-additives-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the gene therapy for inherited genetic disorders market from 2026–2035 with trusted insights from The Business Research Company

What upper market value could the Gene Therapy For Inherited Genetic Disorders Market reach by 2030 starting from 2026 levels?

The gene therapy for inherited genetic disorders market size has seen rapid expansion in recent years. This market is set to expand from $4.05 billion in 2025 to $4.84 billion in 2026, achieving a compound annual growth rate (CAGR) of 19.3%. Historically, the growth can be linked to aspects such as the limited availability of advanced gene therapy techniques, reliance on conventional treatments for genetic disorders, increasing prevalence of inherited genetic diseases, early clinical research on viral vectors, and rising awareness of rare disease management.

The market for gene therapy targeting inherited genetic disorders is projected to experience swift expansion in the coming years. This market is anticipated to reach $9.69 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 19.0%. This projected growth can be ascribed to several factors, including the advancement of innovative viral vectors and gene editing technologies, the broadening scope of RNA-based treatments, the growing uptake of ex vivo stem cell therapies, increasing financial commitments towards personalized gene therapies, and the enhanced capacity of hospitals and specialty clinics for administering gene therapies. Key trends expected during this period involve the wider application of viral vector-based therapies for uncommon genetic conditions, an increase in ex vivo gene therapy uses, the escalating embrace of RNA-based therapeutics, a heightened emphasis on addressing neurological and ophthalmic ailments, and the incorporation of personalized medicine into gene therapy practices.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27293&type=smp

Which Drivers Are Influencing Long-Term Growth In The Gene Therapy For Inherited Genetic Disorders Market?

The escalating need for personalized medicine is anticipated to fuel the expansion of the gene therapy for inherited genetic disorders market moving forward. Personalized medicine involves customizing medical interventions based on an individual’s genetic profile and personal attributes to achieve optimal patient care. The prevalence of personalized medicine is growing due to breakthroughs in genetic technologies, which facilitate easier and more economical customization of treatments to a person’s distinct genetic composition. This approach enhances gene therapy by tailoring therapies to each patient’s specific genetic makeup, thereby ensuring accurate gene targeting and delivery, while simultaneously improving efficacy and mitigating adverse effects. For illustration, in February 2024, as reported by the Personalized Medicine Coalition, a US-based non-profit organization, the United States Food and Drug Administration (FDA) authorized 16 novel personalized treatments for patients with rare diseases in 2023, an increase from 6 in 2022. These newly approved personalized treatments in 2023 further encompassed seven cancer medications and three for other ailments and conditions. Consequently, the increasing demand for personalized medicine is driving the growth of the gene therapy for inherited genetic disorders market.

Which Segments Are Driving Activity In The Gene Therapy For Inherited Genetic Disorders Market?

The gene therapy for inherited genetic disorders market covered in this report is segmented –

1) By Type: Viral Vector-Based Therapies, Gene Editing Techniques, Ribonucleic Acid-Based Therapies, Ex Vivo Gene Therapy

2) By Application: Inherited Metabolic Disorders, Neurological Disorders, Cardiovascular Disorders, Musculoskeletal Disorders, Ophthalmic Disorders

3) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users

Subsegments:

1) By Viral Vector-Based Therapies: Adenovirus Vectors, Adeno-Associated Virus (AAV) Vectors, Lentivirus Vectors

2) By Gene Editing Techniques: Zinc Finger Nucleases (ZFNs), Transcription Activator-Like Effector Nucleases (TALENs), Meganucleases

3) By Ribonucleic Acid-Based Therapies: Small Interfering Ribonucleic Acid, Antisense Oligonucleotides (ASOs), Messenger Ribonucleic Acid (mRNA) Therapies

4) By Ex Vivo Gene Therapy: Hematopoietic Stem Cell Gene Therapy, Mesenchymal Stem Cell Gene Therapy, Induced Pluripotent Stem Cell (iPSC) Therapy

How Are New Market Trends Shaping The Landscape Of The Gene Therapy For Inherited Genetic Disorders Market?

Major companies in the gene therapy for inherited genetic disorders market are focused on developing innovative solutions, such as ex-vivo CRISPR/Cas9-based gene-edited cell therapies, to address the increasing demand for one-time, potentially curative treatments. These treatments aim to lessen lifelong dependence on transfusions, repeated hospitalizations, and high chronic-care costs for inherited blood and metabolic disorders. The ex-vivo CRISPR/Cas9 gene-edited cell therapy process involves harvesting a patient’s hematopoietic stem cells, utilizing CRISPR/Cas9 to precisely edit disease-causing genes (or regulatory elements that increase protective fetal hemoglobin), and subsequently reinfusing the modified cells to allow them to engraft and deliver long-term therapeutic benefits. For instance, in December 2023, Vertex Pharmaceuticals, a US-based biopharmaceutical company, received U.S. Food and Drug Administration (FDA) approval and commercial availability for CASGEVY (exagamglogene autotemcel), a CRISPR/Cas9-based, ex-vivo gene-edited cell therapy for sickle cell disease, which is an inherited genetic disorder. CASGEVY is manufactured from a patient’s own hematopoietic stem cells that are genetically altered to increase fetal hemoglobin. The product’s composition centers on autologous stem cells modified with CRISPR/Cas9; its functionality is to raise durable fetal hemoglobin levels that prevent red-blood-cell sickling; unique features include precise genome editing (CRISPR/Cas9) performed ex vivo and a one-time administration with durable effect; its primary application is treating severe sickle cell disease (and related indications under regulatory review), and the main benefits observed in trials are marked reductions in vaso-occlusive crises and transfusion dependence compared with previous standard-of-care.

Which Major Firms Are Strengthening Their Position In The Gene Therapy For Inherited Genetic Disorders Market?

Major companies operating in the gene therapy for inherited genetic disorders market are Sanofi S.A., Novartis AG, Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Genentech, Biomarin Pharmaceutical Inc, Sarepta Therapeutics Inc., Krystal Biotech Inc., Rocket Pharmaceuticals Inc., Sangamo Therapeutics Inc., REGENXBIO Inc., Passage Bio Inc., Voyager Therapeutics Inc., Generation Bio Co., Avrobio Inc, Editas Medicine Inc., MeiraGTx Holdings Plc, uniQure N.V., Intellia Therapeutics Inc., Bluebird Bio Inc, 4D Molecular Therapeutics Inc., CRISPR Therapeutics AG

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/gene-therapy-for-inherited-genetic-disorders-global-market-report

Which Region Shows The Strongest Potential For Future Expansion In The Gene Therapy For Inherited Genetic Disorders Market?

North America was the largest region in the gene therapy for inherited genetic disorders market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene therapy for inherited genetic disorders market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Gene Therapy For Inherited Genetic Disorders Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=27293&type=smp

Browse Through More Reports Similar to the Global Gene Therapy For Inherited Genetic Disorders Market 2026, By The Business Research Company

Asphalt Mixing Plants Market Report 2026

https://www.thebusinessresearchcompany.com/report/asphalt-mixing-plants-global-market-report

Asphalt Pavers Market Report 2026

https://www.thebusinessresearchcompany.com/report/asphalt-pavers-global-market-report

Asphalt Additives Market Report 2026

https://www.thebusinessresearchcompany.com/report/asphalt-additives-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the gene therapy for inherited genetic disorders market from 2025–2034 with trusted insights from The Business Research Company

What Is The Predicted Market Size Of The Gene Therapy For Inherited Genetic Disorders Industry By 2029?

The gene therapy for inherited genetic disorders market size has seen rapid expansion in recent years. This market is set to increase from $3.39 billion in 2024 to $4.05 billion in 2025, progressing at a compound annual growth rate (CAGR) of 19.4%. Historically, this development can be linked to a rise in government initiatives and supportive policies for gene therapy, enhanced accessibility of advanced gene delivery systems, increasing patient demand for effective and curative treatments, the growing number of clinical trials focused on inherited disorders, and improved awareness among healthcare professionals regarding the advantages of gene therapy.

The gene therapy for inherited genetic disorders market size is projected to experience considerable growth in the coming years, escalating to $8.15 billion by 2029 at a compound annual growth rate (CAGR) of 19.1%. This anticipated expansion during the forecast period is driven by factors such as the increasing prevalence of inherited genetic disorders, growing investment and funding in gene therapy research and development, enhanced awareness and diagnosis rates for rare genetic diseases, rising approvals of novel gene therapy products by regulatory agencies, and the expanding adoption of personalized medicine approaches. Major trends for the forecast period include the integration of advanced delivery systems for targeted gene therapy, continuous developments in viral and non-viral vector technologies, advancements in next-generation sequencing facilitating precise diagnosis, technological improvements in the manufacturing and scalability of gene therapies, and the incorporation of artificial intelligence to optimize gene therapy design.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27293&type=smp

Which Factors Are Steering Growth In The Gene Therapy For Inherited Genetic Disorders Market?

The increasing demand for personalized medicine is anticipated to propel the growth of the gene therapy for inherited genetic disorders market moving forward. Personalized medicine involves customizing medical treatments to an individual’s genetic profile and personal characteristics to achieve optimized care. This rise in personalized medicine is largely due to advancements in genetic technologies, which have made tailoring treatments to an individual’s unique genetic makeup both easier and more affordable. Personalized medicine significantly enhances gene therapy by allowing for treatments to be adapted to each patient’s specific genetic profile, ensuring precise gene targeting and delivery while simultaneously improving effectiveness and reducing side effects. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, stated that in 2023, the United States Food and Drug Administration (FDA) gave approval to 16 new personalized treatments for rare disease patients, an increase from six in 2022. The newly approved personalized treatments for 2023 also encompassed seven cancer drugs and three for other diseases and conditions. Therefore, the escalating demand for personalized medicine is a key driver for the growth of the gene therapy for inherited genetic disorders market.

Which Segment Accounts For The Largest Share In The Gene Therapy For Inherited Genetic Disorders Market?

The gene therapy for inherited genetic disorders market covered in this report is segmented

1) By Type: Viral Vector-Based Therapies, Gene Editing Techniques, Ribonucleic Acid-Based Therapies, Ex Vivo Gene Therapy

2) By Application: Inherited Metabolic Disorders, Neurological Disorders, Cardiovascular Disorders, Musculoskeletal Disorders, Ophthalmic Disorders

3) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users

Subsegments:

1) By Viral Vector-Based Therapies: Adenovirus Vectors, Adeno-Associated Virus (AAV) Vectors, Lentivirus Vectors

2) By Gene Editing Techniques: Zinc Finger Nucleases (ZFNs), Transcription Activator-Like Effector Nucleases (TALENs), Meganucleases

3) By Ribonucleic Acid-Based Therapies: Small Interfering Ribonucleic Acid, Antisense Oligonucleotides (ASOs), Messenger Ribonucleic Acid (mRNA) Therapies

4) By Ex Vivo Gene Therapy: Hematopoietic Stem Cell Gene Therapy, Mesenchymal Stem Cell Gene Therapy, Induced Pluripotent Stem Cell (iPSC) Therapy

Which Long-Term Trends Will Play A Crucial Role In The Gene Therapy For Inherited Genetic Disorders Market?

Major companies within the gene therapy for inherited genetic disorders market are concentrating on advancing solutions, such as establishing gene therapy companies, to devise targeted, safer, and more effective treatments that address the underlying causes of genetic diseases. A gene therapy establishment refers to a biotechnology or pharmaceutical entity specializing in researching, developing, and commercializing gene therapy remedies aimed at correcting or modifying defective genes responsible for inherited genetic disorders. For instance, in November 2022, Replay, a US-based genome writing company, introduced Telaria, a significant DNA HSV gene therapy firm. This company marks the second product company utilizing its high payload capacity herpes simplex virus (HSV) delivery vector, synHSV, and its primary focus is recessive dystrophic epidermolysis bullosa (RDEB), a severe genetic skin condition. The company was co-founded by leading HSV scientists and genetic skin disease experts with the objective of creating transformative gene therapies for these rare skin conditions. This launch follows Replay’s first gene therapy company, Eudora, which targets retinal diseases. Replay’s innovative structure differentiates technology development from therapeutic development by allocating them to distinct product companies focused on specific disease areas.

Who Are The Dominant Players In The Gene Therapy For Inherited Genetic Disorders Market Today?

Major companies operating in the gene therapy for inherited genetic disorders market are Sanofi S.A., Novartis AG, Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Genentech, Biomarin Pharmaceutical Inc, Sarepta Therapeutics Inc., Krystal Biotech Inc., Rocket Pharmaceuticals Inc., Sangamo Therapeutics Inc., REGENXBIO Inc., Passage Bio Inc., Voyager Therapeutics Inc., Generation Bio Co., Avrobio Inc, Editas Medicine Inc., MeiraGTx Holdings Plc, uniQure N.V., Intellia Therapeutics Inc., Bluebird Bio Inc, 4D Molecular Therapeutics Inc., CRISPR Therapeutics AG.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/gene-therapy-for-inherited-genetic-disorders-global-market-report

What Regional Factors Are Accelerating Growth In The Gene Therapy For Inherited Genetic Disorders Market?

North America was the largest region in the gene therapy for inherited genetic disorders market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene therapy for inherited genetic disorders market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=27293&type=smp

Browse Through More Reports Similar to the Global Gene Therapy For Inherited Genetic Disorders Market 2025, By The Business Research Company

Asphalt Mixing Plants Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/asphalt-mixing-plants-global-market-report

Asphalt Additives Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/asphalt-additives-global-market-report

Plumbing Fixtures And Fittings Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/plumbing-fixtures-and-fittings-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Is The Gene Therapy For Inherited Genetic Disorders Market Size Likely To Evolve From 2025 Through 2034?

The gene therapy for inherited genetic disorders market size has experienced rapid expansion in recent years. It is projected to expand from $3.39 billion in 2024 to $4.05 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 19.4%. Historically, this growth can be ascribed to several factors, including a rise in government initiatives and conducive policies supporting gene therapy, enhanced availability of sophisticated gene delivery systems, increased patient desire for effective and curative therapies, the expanding scope of clinical trials focused on inherited disorders, and heightened understanding among healthcare professionals regarding the advantages of gene therapy.

The gene therapy for inherited genetic disorders market is projected to expand significantly in the coming years. It is forecast to grow to $8.15 billion by 2029, achieving a compound annual growth rate (CAGR) of 19.1%. This anticipated growth during the forecast period is driven by factors such as the increasing prevalence of inherited genetic disorders, growing investment and funding in gene therapy research and development, enhanced awareness and diagnosis rates of rare genetic diseases, a rise in regulatory approvals for novel gene therapy products, and the expanding adoption of personalized medicine approaches. Key trends for this period include the integration of advanced delivery systems for targeted gene therapy, ongoing developments in viral and non-viral vector technologies, advancements in next-generation sequencing enabling precise diagnosis, technological improvements in the manufacturing and scalability of gene therapies, and the incorporation of artificial intelligence to optimize gene therapy design.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27293&type=smp

Which Industry Drivers Are Expected To Accelerate The Gene Therapy For Inherited Genetic Disorders Market From 2025 To 2029?

The increasing need for personalized medicine is anticipated to drive the expansion of the gene therapy for inherited genetic disorders market in the future. This approach involves customizing medical interventions based on an individual’s genetic makeup and unique characteristics to provide optimal care. The prevalence of personalized medicine is growing, driven by progress in genetic technologies that facilitate easier and more cost-effective customization of treatments according to a person’s specific genetic profile. It significantly enhances gene therapy by adapting treatments to fit each patient’s distinct genetic blueprint, thereby ensuring accurate gene targeting and delivery, improving efficacy, and minimizing adverse reactions. As an illustration, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the United States Food and Drug Administration (FDA) sanctioned 16 novel personalized treatments for patients with rare diseases in 2023, a considerable increase from six approvals in 2022. Among the new personalized treatments approved in 2023 were also seven medications for cancer and three for various other diseases and conditions. Consequently, the escalating demand for personalized medicine is fueling the growth within the gene therapy for inherited genetic disorders market.

What Are The Major Segments Identified In The Gene Therapy For Inherited Genetic Disorders Market?

The gene therapy for inherited genetic disorders market covered in this report is segmented

1) By Type: Viral Vector-Based Therapies, Gene Editing Techniques, Ribonucleic Acid-Based Therapies, Ex Vivo Gene Therapy

2) By Application: Inherited Metabolic Disorders, Neurological Disorders, Cardiovascular Disorders, Musculoskeletal Disorders, Ophthalmic Disorders

3) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users

Subsegments:

1) By Viral Vector-Based Therapies: Adenovirus Vectors, Adeno-Associated Virus (AAV) Vectors, Lentivirus Vectors

2) By Gene Editing Techniques: Zinc Finger Nucleases (ZFNs), Transcription Activator-Like Effector Nucleases (TALENs), Meganucleases

3) By Ribonucleic Acid-Based Therapies: Small Interfering Ribonucleic Acid, Antisense Oligonucleotides (ASOs), Messenger Ribonucleic Acid (mRNA) Therapies

4) By Ex Vivo Gene Therapy: Hematopoietic Stem Cell Gene Therapy, Mesenchymal Stem Cell Gene Therapy, Induced Pluripotent Stem Cell (iPSC) Therapy

What Are The Major Trends Driving The Growth Of The Gene Therapy For Inherited Genetic Disorders Market?

Leading companies operating in the gene therapy for inherited genetic disorders market are concentrating on developing advanced solutions, such as establishing gene therapy firms, to deliver targeted, safer, and more effective treatments that address the underlying causes of genetic diseases. A gene therapy establishment refers to a biotechnology or pharmaceutical entity specializing in the research, development, and commercialization of gene therapy treatments aimed at correcting or modifying defective genes responsible for inherited genetic disorders. For instance, in November 2022, Replay, a US-based genome writing company, unveiled Telaria, a big DNA HSV gene therapy company. This represents Replay’s second product company, leveraging its high payload capacity herpes simplex virus (HSV) delivery vector, synHSV, with its primary indication being recessive dystrophic epidermolysis bullosa (RDEB), a severe genetic skin condition. The company was co-founded by leading HSV scientists and genetic skin disease experts, with the goal of creating transformative gene therapies for these rare skin diseases. This introduction comes after Replay’s first gene therapy company, Eudora, which targets retinal diseases. Replay’s innovative structure segregates technology development from therapeutic development within distinct product companies focused on specific disease areas.

Which Major Industry Participants Are Leading The Gene Therapy For Inherited Genetic Disorders Market Growth?

Major companies operating in the gene therapy for inherited genetic disorders market are Sanofi S.A., Novartis AG, Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Genentech, Biomarin Pharmaceutical Inc, Sarepta Therapeutics Inc., Krystal Biotech Inc., Rocket Pharmaceuticals Inc., Sangamo Therapeutics Inc., REGENXBIO Inc., Passage Bio Inc., Voyager Therapeutics Inc., Generation Bio Co., Avrobio Inc, Editas Medicine Inc., MeiraGTx Holdings Plc, uniQure N.V., Intellia Therapeutics Inc., Bluebird Bio Inc, 4D Molecular Therapeutics Inc., CRISPR Therapeutics AG.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/gene-therapy-for-inherited-genetic-disorders-global-market-report

How Do Regional Market Performances Compare Within The Gene Therapy For Inherited Genetic Disorders Industry?

North America was the largest region in the gene therapy for inherited genetic disorders market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene therapy for inherited genetic disorders market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Gene Therapy For Inherited Genetic Disorders Market Report:

https://www.thebusinessresearchcompany.com/customise?id=27293&type=smp

Browse Through More Reports Similar to the Global Gene Therapy For Inherited Genetic Disorders Market 2025, By The Business Research Company

Asphalt Mixing Plants Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/asphalt-mixing-plants-global-market-report

Asphalt Pavers Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/asphalt-pavers-global-market-report

Asphalt Additives Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/asphalt-additives-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only._x000D_

_x000D_

#What Are the Latest Market Insights for the Gene Therapy For Inherited Genetic Disorders Industry?#_x000D_

In recent times, the market for gene therapy for inherited genetic disorders has shown significant growth. The market forecast suggests a growth from $3.39 billion in 2024 to $4.05 billion in 2025, showing a compound annual growth rate (CAGR) of 19.4%. The historic growth can be linked to factors such as enhanced government strategies and backing for gene therapy, improved gene delivery systems becoming more accessible, rising patient need for effective curative treatments, an increase in clinical trials focusing on inherited disorders, and an uptick in comprehension of gene therapy advantages amongst healthcare professionals._x000D_

_x000D_

The market size for gene therapy for inherited genetic disorders is projected to experience accelerated expansion in the coming years. It is set to increase to $8.15 billion in 2029, with a compound annual growth rate (CAGR) of 19.1%. The surge during the forecast period can be associated with the rising prevalence of inherited genetic disorders, enhancements in funding and investments for gene therapy research and development, escalating awareness and diagnosis rates of rare genetic conditions, increasing approvals of new gene therapy products by regulatory bodies, and the expanding use of personalized medicine approaches. Significant trends expected in the forecast period encompass the inclusion of advanced delivery systems for targeted gene therapy, progression in viral and non-viral vector technology, advancements in next-generation sequencing facilitating precise diagnosis, technological enhancements in production and scalability of gene therapies, and use of artificial intelligence to perfect gene therapy design._x000D_

_x000D_

#Download The Free Sample Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=27293&type=smp_x000D_

_x000D_

#What Forces Are Driving The Growth Of The Gene Therapy For Inherited Genetic Disorders Industry?#_x000D_

The growing preference for personalized medicine is anticipated to accelerate the expansion of the market for gene therapy for inherited genetic disorders. Personalized medicine represents the adjustment of medical care to match the genetic profile and individual features of a patient for enhanced treatment. Progress in genetic technology has enhanced the prominence of personalized medicine by making it simpler and more cost-effective to customize treatment to a person’s specific genetic composition. Personalized medicine improves gene therapy by adjusting treatments to fit each patient’s specific genetic profile, guaranteeing accurate gene targeting and delivery while magnifying effectiveness and minimizing side-effects. For example, the Personalized Medicine Coalition, a non-profit organization based in the US, reported in February 2024 that in 2023, the United States Food and Drug Administration (FDA) authorized 16 new personalized treatments for rare disease patients, which was a rise from six in 2022. The freshly approved personalized treatments for 2023 also incorporated seven cancer drugs and three for other diseases and health issues. Hence, the surging interest in personalized medicine is fueling the expansion of the gene therapy market for inherited genetic disorders._x000D_

_x000D_

#What Is The Overview Of Market Segmentation In The Gene Therapy For Inherited Genetic Disorders Industry?#_x000D_

The gene therapy for inherited genetic disorders market covered in this report is segmented_x000D_

_x000D_

1) By Type: Viral Vector-Based Therapies, Gene Editing Techniques, Ribonucleic Acid-Based Therapies, Ex Vivo Gene Therapy_x000D_

2) By Application: Inherited Metabolic Disorders, Neurological Disorders, Cardiovascular Disorders, Musculoskeletal Disorders, Ophthalmic Disorders_x000D_

3) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users_x000D_

_x000D_

Subsegments:_x000D_

1) By Viral Vector-Based Therapies: Adenovirus Vectors, Adeno-Associated Virus (AAV) Vectors, Lentivirus Vectors_x000D_

2) By Gene Editing Techniques: Zinc Finger Nucleases (ZFNs), Transcription Activator-Like Effector Nucleases (TALENs), Meganucleases_x000D_

3) By Ribonucleic Acid-Based Therapies: Small Interfering Ribonucleic Acid, Antisense Oligonucleotides (ASOs), Messenger Ribonucleic Acid (mRNA) Therapies_x000D_

4) By Ex Vivo Gene Therapy: Hematopoietic Stem Cell Gene Therapy, Mesenchymal Stem Cell Gene Therapy, Induced Pluripotent Stem Cell (iPSC) Therapy_x000D_

_x000D_

#What Future Market Trends Are Projected For The Gene Therapy For Inherited Genetic Disorders Industry?#_x000D_

Significant enterprises in the inherited genetic disorders gene therapy market are prioritizing the development of forward-thinking solutions, such as gene therapy foundations, to deliver precise, reliable and efficient treatments that tackle the fundamental causes of genetic illnesses. A gene therapy foundation is a biotech or pharmaceutical firm that excels in researching, crafting, and marketing gene therapy treatments intended to rectify or alter faulty genes which cause inherited genetic disorders. For instance, Replay, an American company that specializes in genome writing, unveiled Telaria, an extensive DNA HSV gene therapy company, in November 2022. This is the second product company that capitalizes on its high payload capacity herpes simplex virus (HSV) delivery vector, synHSV, and its primary implication is recessive dystrophic epidermolysis bullosa (RDEB), an intense genetic skin disorder. The company was initiated by eminent HSV scientists and experts in genetic skin diseases, with the intention to generate revolutionary gene therapies for these uncommon skin diseases. This introduction comes after Replay’s initial gene therapy company, Eudora, which targets diseases of the retina. Replay’s innovative setup segregates technology advancement from therapeutic development across unique product companies that concentrate on particular disease fields._x000D_

_x000D_

#Who Are The Primary Players Operating Across The Global Gene Therapy For Inherited Genetic Disorders Market?#_x000D_

Major companies operating in the gene therapy for inherited genetic disorders market are Sanofi S.A., Novartis AG, Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Genentech, Biomarin Pharmaceutical Inc, Sarepta Therapeutics Inc., Krystal Biotech Inc., Rocket Pharmaceuticals Inc., Sangamo Therapeutics Inc., REGENXBIO Inc., Passage Bio Inc., Voyager Therapeutics Inc., Generation Bio Co., Avrobio Inc, Editas Medicine Inc., MeiraGTx Holdings Plc, uniQure N.V., Intellia Therapeutics Inc., Bluebird Bio Inc, 4D Molecular Therapeutics Inc., CRISPR Therapeutics AG. _x000D_

_x000D_

#Get The Full Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/report/gene-therapy-for-inherited-genetic-disorders-global-market-report_x000D_

_x000D_

#Which Region Offers The Most Growth Potential For The Gene Therapy For Inherited Genetic Disorders Market Through 2029?#_x000D_

North America was the largest region in the gene therapy for inherited genetic disorders market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene therapy for inherited genetic disorders market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Request For A Customized Report:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=27293&type=smp_x000D_

_x000D_

#About The Business Research Company:#_x000D_

_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 7882 955267 & +91 8897263534_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model